Teva generic fish oil pill win ruffles Amarin investors
This article was originally published in Scrip
Executive Summary
Amarin investors were slightly worried on 8 April after Teva revealed it had gained FDA approval of a generic version of GlaxoSmithKline's Lovaza (omega-3-acid ethyl esters), which is likely to make the market even more competitive for Amarin's fish oil pill Vascepa, which already is struggling to gain a foothold.
You may also be interested in...
Vascepa Included In European Dyslipidemia Guidelines Ahead Of Approval
Amarin won't seek approval in the EU until later this year, but doctors there are encouraged to consider Vascepa for patients with high triglycerides despite statin therapy. Also, PCSK9 inhibitor guidelines were solidified for very high risk patients.
'That's Huge, Folks': Amarin's Vascepa Cuts CV Risk By 25% On Top Of Statins
Cardiovascular outcomes data exceeded expectations for the fish oil pill, vindicating Amarin, which has fought long and hard for Vascepa's place in the CV disease prevention market. A filing based on REDUCE-IT is expected in early 2019.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.